ストックスクリーナーアプリを入手
8.47
14.53%
-1.44
アフターアワーズ：
8.70
0.23
+2.72%
前日終値:
$9.91
開ける：
$9.81
24時間の取引高:
94,851
Relative Volume:
2.03
時価総額：
$84.59M
収益：
$2.09M
当期純損益:
$-5.28M
株価収益率:
-12.64
EPS:
-0.67
ネットキャッシュフロー:
$-3.64M
1週間 パフォーマンス:
+7.62%
1か月 パフォーマンス:
+10.00%
6か月 パフォーマンス:
+90.34%
1年 パフォーマンス:
+44.79%
1日の値動き範囲:
$8.45
$9.8273
1週間の範囲:
$7.7742
$11.68
52週間の値動き範囲:
$3.7223
$11.78
Nutriband Inc Stock (NTRB) Company Profile
NTRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NTRB
Nutriband Inc
|
8.47 | 84.59M | 2.09M | -5.28M | -3.64M | -0.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nutriband Inc Stock (NTRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-22 | 開始されました | Noble Capital Markets | Outperform |
Nutriband Inc (NTRB) 最新ニュース
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-Up for Aversa?? Fentanyl Abuse Deterrent Fentanyl Patch - MarketScreener
Nutriband and Kindeva Complete Commercial Manufacturing - GlobeNewswire
Nutriband and Kindeva Complete Commercial Manufacturing Process - GuruFocus
Nutriband (NTRB) Advances Aversa Fentanyl Manufacturing Process | NTRB Stock News - GuruFocus
Nutriband, Kindeva complete commercial manufacturing process scale-up for Aversa - TipRanks
Revolutionary Abuse-Deterrent Fentanyl Patch Completes Manufacturing Scale-up: $200M Market Potential - Stock Titan
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development - citybuzz -
(NTRB) Proactive Strategies - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology - The Globe and Mail
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology - citybuzz -
Nutriband secures US patent for abuse deterrent patch technology By Investing.com - Investing.com South Africa
Nutriband issued U.S. patent for transdermal abuse deterrent technology - TipRanks
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology - The Manila Times
Nutriband secures US patent for abuse deterrent patch technology - Investing.com Australia
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband (NTRB) Secures Patent for Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband Secures Game-Changing Patent for First-Ever Abuse-Deterrent Fentanyl Patch Technology - Stock Titan
Nutriband (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology - Barchart.com
Nutriband (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value - The Globe and Mail
Nutriband Inc. Pioneers Abuse-Deterrent Technology with AVERSA, Targets $800 Million Market Potential - citybuzz -
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference - GlobeNewswire
Nutriband (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference - The Globe and Mail
Nutriband CEO Reveals Growth Strategy: Exclusive Virtual Presentation at Noble Capital Conference - Stock Titan
Nutriband reports Q1 revenue up 63% y/y at $667K - TipRanks
Nutriband First Quarter 2026 Earnings: EPS Beats Expectations - Yahoo Finance
Nutriband (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development - The Globe and Mail
Nutriband Inc. Reports Revenue Results for the First Quarter Ended April 30, 2025 - MarketScreener
Nutriband Inc. Provides Update on the Development of AVERSA Fentanyl - MarketScreener
Nutriband (NTRB) Expands Kinesiology Tape Production and Advances Drug Delivery Solutions | NTRB Stock News - GuruFocus
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - The Manila Times
Nutriband Inc. Quarterly Report Highlights Record Revenue - GlobeNewswire
Nutriband Q1 Revenue Surges 63% as AVERSA Fentanyl Development Advances | NTRBW Stock News - Stock Titan
Nutriband Inc. (NTRB) reports Q1 loss, misses revenue estimates - FXStreet
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates - MSN
NutriBand Inc. SEC 10-Q Report - TradingView
(NTRB) Investment Analysis - news.stocktradersdaily.com
Nutriband Addresses Opioid Pain Management Challenges with Innovative Transdermal Solution - citybuzz -
Nutriband (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast - Barchart.com
IBN Announces Latest Episode Of The Biomedwire Podcast Featuring Gareth Sheridan, CEO Of Nutriband Inc. - marketscreener.com
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc. - GlobeNewswire
Nutriband (NASDAQ: NTRB) Charts Path To Commercialization - Barchart.com
Stocks in play: Brookfield Corporation - The Globe and Mail
Nutriband Advances Opioid Pain Patch Technology with Strategic Partnership - citybuzz -
Concern Rises over Market Valutions and Structural Vibrations - The Globe and Mail
(NTRB) On The My Stocks Page - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances - Barchart.com
Nutriband Expands Market Presence Through Strategic Health Industry Partnerships - citybuzz -
Why Isn't Palantir's Stock Taking Off After Another Strong Quarter? - The Globe and Mail
Nutriband (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch - Barchart.com
Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch Amid Opioid Crisis Regulatory Changes - citybuzz -
Nutriband (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape - Barchart.com
Nutriband Inc (NTRB) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
2.14%
大文字化:
|
ボリューム (24 時間):